Close

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation of Claims against CTI BioPharma Corp. And Strongly Encourages Investors to Contact the Firm

February 12, 2016 1:25 PM EST

IRVINE, Calif.--(BUSINESS WIRE)-- Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by CTI BioPharma Corp. (“CTI” or the “Company”) (Nasdaq: CTIC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased shares of CTI during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation will focus on whether the Company failed to disclose that: (1) CTI’s clinical trials showed that patient deaths were related to pacritinib usage; (2) CTI’s application for the approval of pacritinib would likely be withdrawn; (3) the Company’s future revenues were impaired; and (4) that the company lacked adequate internal controls.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

Source: Khang & Khang LLP



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases